chrisvoncsefalvay/vaers-outcomes huggingface dataset:
adverse events: nausea,  light headed (did not pass out) , dizziness, slight headache   treatment: water, squatted down to get low to the ground  outcomes: symptoms passed after a few minutes and did not return
Patient recieved vaccine and got hives down both arms. Patient was informed to take Benadryl 50mg by mouth and call his Doctor. Unable to reach patient to see how he is doing.
Swollen left thigh, take Motrin/Advil for pain left thigh measured 27cm, right thigh measured 25cm.
head colds; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient. The patient reported for himself and his wife. This is first of two reports.  A male patient received bnt162b2 (BNT162B2), administration date 10Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NASOPHARYNGITIS (non-serious) with onset Mar2021, outcome "unknown", described as "head colds".  Additional information: Age of patient: 80, unit unknown. Product: Pfizer-Biontech Covid-19 Vaccine. The patient and his wife had their 1st Pfizer vaccine dose on 10Mar2021, and the next vaccine dose is due tomorrow. The patient stated he and his wife had head colds, no fever. The patient asked if they should reschedule their 2nd dose and if it is ok to have a cold when they get the vaccine.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021361868 Same reporter/vaccine/events, different patient
Unwell; Flushed; Mild nausea; This case was reported by a consumer via call center representative and described the occurrence of unwell in a 84-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In October 2021, the patient received the 1st dose of Shingrix. In October 2021, less than 3 weeks after receiving Shingrix, the patient experienced unwell, flushing and nausea. The patient was treated with ambiguous medication nos (Cortisone (Nos)). On an unknown date, the outcome of the unwell, flushing and nausea were unknown.   It was unknown if the reporter considered the unwell, flushing and nausea to be related to Shingrix.  Additional details provided were as follows: The case was reported by patient's husband. The patient received first dose of Shingrix 3 weeks before the date of reporting. Since receiving the vaccine, the patient felt unwell, had periodic mild nausea, and felt a little flushed (symptomatic). The reporter inquired if these were side effects and their duration were common. The reporter also inquired if they should get second dose. The reporter stated that his doctor prescribed Cortisone 20 mg once daily for 5 days for symptoms. The reporter consented to follow-up. The case has been linked with case US2021223603, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021223576:same reporter
Sleeping 16 hours daily x 3 day, swelling of both arms. Sleeping sent home due to fatigue sleeping 16 hours - x 2 days.
I observed  patient turning his head forcefully, asked him he has any pain, he complain he has neck pain. It looks to me he has external jugular vein pain. I took him to ER visit. It seems doctor also not sure much, expected sleeping issue. Suggested to take Advil pain killer. We started to give Advil and also Zyrtech allergy medicine. after 3-4 days, he seems OK now. Now question, is it COVID vaccine side effects, or something else, he never had this kind of issue, or any know health issue, except seasonal allergy and asthma.  Last two years patient did not have allergy and Asthma problem and no medicines are given. Should patient to take second dose of vaccines, it is really scary things.  It seems ER doctors are helpless and we do not know the real issue of vein pain.
Dermatitis type rash beginning on left arm then spreading to BUE, upper chest, inner knees, torso, intensely itchy almost hives but not quite. Itched so intense that I itched my skin open. Saw MD was put on prednisone, due to no diagnosis and intensity of itch requested permethrin cream for scabies. I am an LPN at a LTC facility, I sleep in bed with my toddler and not one other person with any of these symptoms so scabies was ruled out. We had a covid outbreak that ended around xmas 2020 I did not catch covid. Rash eventually went away after 2 weeks. I still have some scarring.
Itching at abdomen, knee, right arm, and hand. BPs 166/93 (pulse 103), 155/91 (pulse 89),  Given Benadryl 50 mg PO, water, juice.
Daughter received HPV on 09/11/2007.  2 weeks after receiving the vaccine she started breaking out in a rash on her chest. It rapidly spread to her back, up her neck, her face and covered her entire trunk within a few days.  It continued to spread into her groin area, her arms, and her legs down to her ankles.  This all took place starting 09/27/2007.  I had to to her PCP, whom she received the shot and to a dermatologist, who first diagnosed her with Pitariosis Rosea.  The dermatologist did a biopsy and came back with "eczema".  The rash continued to break out until there was barely any skin NOT covered with this rash.  My daughter started swelling.  I immediately demanded full blood work up.  All of the counts came back as normal. I scheduled an appointment with an allergist, thinking that maybe she was allergic to something.  All tests were negative.  The only way we got her cleared up was with Prednisone.  After she did her round with Prednisone, she broke out again, but not as extreme.  My daughter had this rash for 2 months.  She is now scared from the biopsy and during all of this she has "white spots" where the pigment in her skin is gone.  She is possibly scared for life.
Rash on back, face, feet and belly. Chickenpox reaction. ProQuad reaction.
Mom called 12/7/2021 the day after the vaccine was given. She stated that the patient fainted 3-4 times that morning in the shower about 5:00 AM. Stated the patient was experiencing stomach pain, pale skin, and nausea. EMS was called and she was transported to the hospital. After head ct and chest xray showed everything was okay, they thought it was due to the vaccine given. Mother stated that all her symptoms have resolved other than the sore arm. Mother stated she had no problems after the first vaccine and wanted to call to inform me of the events this morning and explain they thought it was due to the 2nd dose of Bexsero (Men B).
Wed. 6/9/10 mild discomfort at injection site (left deltoid), Thurs. 6/10/10 became painful to touch and limited range of motion, pain increases when left arm is abducted away from the body, 6/11/10 Fri. experiencing more intense pain, rates pain 7 on pain scale.
After receiving the COVID-19 vaccine patient experienced blurred vision, feeling of fainting, numbness on hand, dizziness. Patient sat down on the floor. 911 was called and arrived within a few minutes-Patient had low blood pressure and was taken to the hospital for observation
This spontaneous report as received from a nurse refers to unspecified patient of unknown age and gender. No medical history and concurrent conditions were reported. The nurse reported that on an unknown date and time after 02-FEB-2015, unspecified number of patients were inadvertently vaccinated with ROTATEQ (unspecified dose and route) lot # K00900, expiry date 04-MAY-2016 and lot # K010224, expiry date 13-MAY-2016. On an unspecified date, the vaccine had been improperly stored. No adverse effects were reported. There was no product quality complaints (PQC) involved. The outcome of the event was unknown. No further information was provided. This is one of several reports received from the same reporter. Additional information has been requested.
Fussiness, extreme incessant crying, erythema (large) at site of injection R upper ant thigh.
[Pfizer Covid Vaccine] use for COVID-19 under Emergency Use Authorization (EUA): covid pneumonia and respiratory failure in a patient who received two pfizer covid shots
Started getting itchy behind ears and itching all night long. Took antihistamine, didn't work. To medical center. No shortness of breath, cough. No difficulty swallowing, eating or talking. Rash mostly upper trunk some on arms and face, neck and ears. Give BENADRYL and prednisone for couple days.
Redness, swelling, itching, burning, and headache starting around 6pm on 11/4/13. Pt used TYLENOL to relieve headache that evening. Prescriptions for MEDROL dose pack and betamethasone cream 11/7/13.
injection site pain; feeling feverish; This is a spontaneous report from a contactable nurse reported for herself. This 51-year-old female patient (No pregnant) received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EL1283), via an unspecified route of administration in right arm on 07Jan2021 at single dose for COVID-19 immunization. Medical history included childhood asthma, Type 2 diabetes mellitus (NIDDM), Latex allergies. Concomitant medication included Metformin, Glyburide, Lisinopril, empagliflozin (JARDIANCE), sitagliptin (JANUVIA), Atorvastatin, salbutamol (PROVENTIL), fluticasone propionate, salmeterol xinafoate (ADVAIR), paracetamol (TYLENOL), colecalciferol (D3), Diosmin, Niacin, fluticasone propionate (FLONASE), ascorbic acid (VIT C), MVI. Patient received first dose of BNT162B2 intramuscular in left arm on 17Dec2020 02:45 PM and experienced injection site pain, increased soreness in 24 hrs, Bleeding at left arm injection site, Flu like symptoms at the 12th hour of vaccination, feeling unwell, fatigue, mild headache. After the second dose on 07Jan2021, the patient experienced injection site pain and feeling feverish the first hour. The outcome of events was unknown. No COVID prior vaccination, no COVID tested post vaccination.  No follow-up attempts are possible. No further information is expected.
Presented with dizziness, sinus pressure, post nasal drip, lightheadedness, unsteady gait, acute labrynthitis.  Meclizine/Antivert 12.5 by mouth 3x's per day.
Severe Diarrhea; soreness of left arm; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Severe Diarrhea) and PAIN IN EXTREMITY (soreness of left arm) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Mar-2021, the patient experienced DIARRHOEA (Severe Diarrhea) and PAIN IN EXTREMITY (soreness of left arm). On 16-Mar-2021, DIARRHOEA (Severe Diarrhea) had resolved. At the time of the report, PAIN IN EXTREMITY (soreness of left arm) outcome was unknown. Not Provided          No Concomitant medications were reported. No Treatments were reported.
On 30-05-2023 Lowest temp was recorded at 35.8F) , and on 05-06-2023 the lowest 33.7 F). The vial sat at room temp for 15 mins; After excursion vaccine was administered to patient; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (On 30-05-2023 Lowest temp was recorded at 35.8F) , and on 05-06-2023 the lowest 33.7 F). The vial sat at room temp for 15 mins), POOR QUALITY PRODUCT ADMINISTERED (After excursion vaccine was administered to patient) and NO ADVERSE EVENT (No adverse event) in an elderly patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7180B) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .05 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (On 30-05-2023 Lowest temp was recorded at 35.8F) , and on 05-06-2023 the lowest 33.7 F). The vial sat at room temp for 15 mins), POOR QUALITY PRODUCT ADMINISTERED (After excursion vaccine was administered to patient) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (On 30-05-2023 Lowest temp was recorded at 35.8F) , and on 05-06-2023 the lowest 33.7 F). The vial sat at room temp for 15 mins), POOR QUALITY PRODUCT ADMINISTERED (After excursion vaccine was administered to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (On 30-05-2023 Lowest temp was recorded at 35.8F) , and on 05-06-2023 the lowest 33.7 F). The vial sat at room temp for 15 mins) and POOR QUALITY PRODUCT ADMINISTERED (After excursion vaccine was administered to patient).    No concomitant information was reported. It was reported that department of health advised vaccine specific refrigerator needed to be used, instead of the dorm-style fridge on site. The vial sat at room temp for 15 mins before admin and then discarded at the end of the day. No treatment information was provided.
My daughter received the HIB vaccine on October 26, 2007. That evening she developed a fever, and we gave her Tylenol. On October 27, 2007, I contacted her physician because her fever was above 100.5 and she was only 2 months old. The fever continued to persist, typically in the 103 degree range. On October 28, 2007, Dr. examined her in the office and ordered blood work and collected a urine sample. The urine test came back ok, and so did the blood work, however, her platelet count was high. On Monday, October 29, 2007, her fever persisted and the physician called us to the office so she could again examine the baby. The fever was around 103 degrees (rectal) and she admitted the baby to the hospital. Patient received 2 antibiotics intraveneously and the fever proceeded to decline. Patient was discharged from the hospital at 5 pm on October 30th, and when we got home from the hospital she developed a rash over her belly, trunk and head. She was uncomfortable that nite until approx. 1 am, when she went to sleep. Until this instance, she never cried like this and she has always (every single nite) slept through the nite and NEVER cries. She continued to remain warm, around 99.90 rectal temp for the next 3 weeks. We even went to an infectious disease specialist at hospital because the hospital, nor the doctors could find the root of an infection, although the doctor's were certain she had an infection of some sort.  12/28/07 Reviewed hospital medical records which reveal patient experienced fever, bloody stool x 1, cough, coarse breath sounds, reduced oral intake & marked purulent nasal congestion.  Seen in pcp office & admitted to hospital 10/29-10/30/2007.   FINAL DX: fever, otitis media, bronchitis & sinusitis. 2/11/08 Reviewed vax record & database updated w/same.
13 patients received  an expired vaccine for a booster dose; Vaccine was stored in the refrigerated after 30-day Use By Date, therefore product storage error was captured.; 13 patients received  an expired vaccine for a booster dose; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (13 patients received  an expired vaccine for a booster dose), PRODUCT TEMPERATURE EXCURSION ISSUE (13 patients received  an expired vaccine for a booster dose) and PRODUCT STORAGE ERROR (Vaccine was stored in the refrigerated after 30-day Use By Date, therefore product storage error was captured.) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045L21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (13 patients received  an expired vaccine for a booster dose). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (13 patients received  an expired vaccine for a booster dose) and PRODUCT STORAGE ERROR (Vaccine was stored in the refrigerated after 30-day Use By Date, therefore product storage error was captured.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (13 patients received  an expired vaccine for a booster dose), PRODUCT TEMPERATURE EXCURSION ISSUE (13 patients received  an expired vaccine for a booster dose) and PRODUCT STORAGE ERROR (Vaccine was stored in the refrigerated after 30-day Use By Date, therefore product storage error was captured.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   She  stated  that she received dosages in January with the same lot number, 045L21A that expired on the 20-Jan-2022 and they were put in the freezer and  from 23-Feb-2022 until the 12-May-2022 they administer them to 13 patients, all booster dosages, after they expired. Gave consent to be follow by safety  Number of doses/vials was13 doses out of 12 vials.  The vial was initially stored in the refrigerator on 20-Jan-2022.  Vaccine was administered  from 23-Feb-2022 until the 12-May-2022.  Vial was underwent temperature excursions  Vial was refrigerated condition at the time of the excursion.   Lot number and Expiration Date*: 045L21A5, Jul-2022  Vial temperatures Maximum 44.6°F  minimum  38.8°F reached.  Vial Excursion duration was 3 months.  No,Visual inspection noting any vaccine state change, they are in seal boxes.  Number of vials/doses impacted: 660 doses, and they have now 520  No any previous excursions with the impacted vial(s).  Patient had no allergy medications, food and other products.   Patient ever had COVID + test or diagnosis was reported as unknown.   Vial was underwent temperature excursions.  No other vaccines given within 1 month prior to Moderna COVID-19 vaccine (type, brand, lot, route,Dose).  No concomitant medication were reported.   No treatment drug were reported.
Patient came in for a flu vaccine with her father.  Patient was given flu vaccine and instructed to wait after injection. Shortly after vaccine given father called out from the room for help. One of the office staff went to room where father stated she had felt dizzy and fell off of exam bed and hit head on floor. Physician was called into room to exam. Father did report the patient had not yet eaten. Patient waited additional time before leaving office. Parent has not called back since to report any additional concerns.
Very sore arm near the imjection site.  Very painful the next day, but less so the next day.
pt recv vax & exp an elevated temp;no other details were known @ the time of this report
Redness and soreness and swelling at the injections site that subsided over 72 hours.
Patient complaint of reaction after 2 nd dose of vaccine symptoms include headache. flushing. tingling tongue. 50mg diphenhydramine administered IM by pharmacist. Blood pressure and heart rate is monitored. Pt was stable after 1 hour without complaint of tingling tongue, or flushing. He was released with feeling of drowsiness from diphenhydramine and was advised not to drive
Severe nausea/vomiting, hypoglycemia, angina, loss of bowels, malaise.
Warmth at the injection site; Erythema at the injection site; Induration at the injection site; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE WARMTH (Warmth at the injection site), VACCINATION SITE ERYTHEMA (Erythema at the injection site) and VACCINATION SITE INDURATION (Induration at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (Warmth at the injection site), VACCINATION SITE ERYTHEMA (Erythema at the injection site) and VACCINATION SITE INDURATION (Induration at the injection site). At the time of the report, VACCINATION SITE WARMTH (Warmth at the injection site), VACCINATION SITE ERYTHEMA (Erythema at the injection site) and VACCINATION SITE INDURATION (Induration at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided.  This case concerned a female of unknown age who experienced expected events of vaccination site warmth, vaccination site erythema, vaccination site induration.  Event onset one week after the first dose of mRNA-1273. Treatment not reported. Event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  On an unknown date (approximately one week after vaccination) the patient experienced VACCINATION SITE WARMTH (Warmth at the injection site), VACCINATION SITE ERYTHEMA (Erythema at the injection site) and VACCINATION SITE INDURATION (Induration at the injection site).  It was reported that the events subsided after a few days.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 25-Mar-2021: Live follow up received on 25-Mar-2021: Event outcome updated.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This case was reported by a nurse and described a 39 year old male patient who did not respond to the hepatitis B vaccine recombinant (Engerix-B) immunization series.  On an unspecified date in 2002 or 2003, the patient received the third dose of Engerix-B.  Approximately 6 to 12 weeks later a hepatitis B surface antibody titer was negative.  The nurse stated that, "All injections were given intramuscularly in the deltoid muscle with a 1 inch needle.  All vaccine is refrigerated and the temperature is monitored daily.  The nurse considered the event to be probably related to vaccination with Engerix-B.
Received COVID shot #2 in the morning.  Went to a GI specialist appointment and noted irregular heart beat on exam.  Referred to see PCP that same day Saw pediatrician, did EKG and PVCs noted and heard. Referred to cardiologist
Reviewed history with patients. Getting shot because of job. Worried since he had reacted to allergy shot in the past with anaphylaxis and Penicillin with a rash. Pre-shot, Two Benadryl tablets 25mg each given orally pre-vaccine. No Issues.
Pt states felt woozy approx 5pm afternoon he received vaccine.  Has had headache/nausea & vomiting.  Vomiting occurred only on 3/26/09.
After immunizations on 01/12/2006, mom states child was irritable between 4-5 hours after receiving them.  Also states child had breathing difficulties after receiving them later in the evening.  Irritability lasted 3-4 days.  Difficulty breathing only lasted that evening.
an hour after injection I could feel lymph nodes beginning to swell in the neck accompanied by a sore throat. late in the day I began to  feel feverish . At 3:00AM the next morning I woke up with a 103 degree  fever and a stiff neck.  my fever lasted over 24 hours  with 103 being the highest temp and 99 being the average. neck stiffness and swollen lymph nodes lasted an extra 2 days.